There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PDS Biotechnology (PDSB – Research Report) and BioSig Technologies (BSGM – Research Report) with bullish sentiments.
PDS Biotechnology (PDSB)
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on PDS Biotechnology, with a price target of $22.00. The company’s shares closed last Thursday at $6.19, close to its 52-week low of $4.10.
According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PDS Biotechnology with a $18.50 average price target, a 190.9% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
BioSig Technologies (BSGM)
Noble Financial analyst Gregory Aurand maintained a Buy rating on BioSig Technologies today and set a price target of $4.00. The company’s shares closed last Thursday at $1.15, close to its 52-week low of $0.90.
According to TipRanks.com, Aurand is ranked #7436 out of 7924 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioSig Technologies with a $4.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PDSB: